Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

The prevalence of “risky behaviour” in adults with cystic fibrosis

Sweat conductivity: An accurate diagnostic test for cystic fibrosis?

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

HbA1c as a screening tool for cystic fibrosis related diabetes

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment Donald R. VanDevanter, Jennifer S.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Journal of Cystic Fibrosis

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Safety and early treatment effects of the CXCR2 antagonist SB in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan,

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited Abaigeal D. Jackson, Leslie Daly,

Controlled clinical trials in cystic fibrosis — are we doing better?

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Claire Keating, Armeen D

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR Jennifer L. Taylor-Cousar, Manu Jain, Tara.

The Journal of Cystic Fibrosis: Sunny perspectives

Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls Jonathan McCormick, Simon A. Ogston,

Journal of Cystic Fibrosis

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis Shahid I. Sheikh, MD, Don Hayes,

A.H. Gifford Journal of Cystic Fibrosis

Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis Anne Orholm Nielsen, Sadaf Qayum, Pierre Nourdine Bouchelouche, Lars Christian.

Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis Elizabeth F. Shead, Charles S. Haworth,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Higher risk of hospitalization among females with cystic fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Characteristics of Malignant Pleural Mesothelioma in Women

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry Sanja Stanojevic, Janet Stocks,

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

CFTR modulators and pregnancy: Our work has only just begun

Vivek Singam, BLA, Kevin R. Patel, BS, Harrison H

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Defining Patient-Prosthesis Mismatch and Its Effect on Survival in Patients With Impaired Ejection Fraction David A. Cotoni, DO, Robert T. Palac, MD,

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Absence of a gender gap in survival

H. White, A.M. Morton, D.G. Peckham, S.P. Conway

Presentation transcript:

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data Ruth H. Keogh, Rhonda Szczesniak, David Taylor-Robinson, Diana Bilton Journal of Cystic Fibrosis Volume 17, Issue 2, Pages 218-227 (March 2018) DOI: 10.1016/j.jcf.2017.11.019 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Final model results: Estimated hazard ratios (HR) and corresponding 95% confidence intervals (CI). The hazard ratios for age at diagnosis are shown graphically, with the shaded area representing the 95% CIs. Journal of Cystic Fibrosis 2018 17, 218-227DOI: (10.1016/j.jcf.2017.11.019) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Estimated survival curves for F508del homozygous individuals (diagnosed at any age) and for individuals with 0 or 1 copy of F508del diagnosed at age 0. Left panel: by F508del status within males and females. Right panel: by sex within F508del group. The shaded areas represent the 95% confidence intervals. The table shows the estimated ages (Est), and 95% confidence intervals (CI), beyond which 75%, 50% and 25% of individuals survive in groups defined by sex and F508del status. Journal of Cystic Fibrosis 2018 17, 218-227DOI: (10.1016/j.jcf.2017.11.019) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Estimated conditional survival curves for F508del homozygous individuals conditional on survival to ages 20, 30, 40, 50; and for F508del heterozygous individuals diagnosed at age 5 and conditional on survival to diagnosis and to ages 20, 30, 40, 50. Left panel: males. Right panel: females. The table shows the estimated ages (Est), and 95% confidence intervals (CI), beyond which 75%, 50% and 25% of individuals survive conditional on survival to a given age in groups defined by sex and F508del status. Journal of Cystic Fibrosis 2018 17, 218-227DOI: (10.1016/j.jcf.2017.11.019) Copyright © 2017 The Authors Terms and Conditions

Fig. 4 Projected survival curves for F508del homozygous individuals diagnosed at birth. Journal of Cystic Fibrosis 2018 17, 218-227DOI: (10.1016/j.jcf.2017.11.019) Copyright © 2017 The Authors Terms and Conditions